1. Introduction {#s0005}
===============

Human endogenous retroviruses (HERVs) are genetic remnants of ancient retroviral infections of the germ line produced during primate evolution which are now transmitted vertically. To date, approximately 8% of the human genome is composed of such retroviral sequences [@bib1]. Most HERVs are dysfunctional due to numerous mutations and deletions. However, those belonging to HERV-K family, contain sequences which are likely to be transcribed.

Many of these HERVs are transcribed and translated under normal physiological conditions. Nevertheless, reactivation of HERVs has frequently been observed in a variety of human tumors suggesting their potential to contribute to malignant progression [@bib2]. Specifically during hemato-oncological processes, several studies have reported the presence of antibodies against HERV-K, overexpression of HERV genes and also the presence of retroviral particles in primary leukemia cells [@bib2]. In addition, *np*9, a small regulatory gene encoded by HERV-K, has a role as a potent viral oncogene and as a critical molecular switch of multiple signaling pathways regulating the growth of certain human myeloid and lymphoblastic leukemia cells [@bib3].

CLL is the most common form of leukemia in Western countries and mainly affects elderly individuals. It follows an extremely variable course, with survival ranging from months to decades. Available treatments often induce disease remission, but almost all patients will relapse and there is a consensus that CLL remains incurable. To date, both an unmutated (UM) profile of immunoglobulin (Ig) VH genes as well as the presence of genetic lesions at chromosome 17p13, or at 11q23 constitute poor prognosis indicators [@bib4]. Several studies have begun to shed light on the nature of genetic predisposition of CLL but the basis of this disorder remains unknown [@bib4; @bib5]. Studies that screened for the presence of a virus expressed at the RNA level in human CLL, by using massive sequencing technology, gave no evidence of a putative exogenous viral candidate as a cause for this disease [@bib6].

In order to gain insight into the role of endogenous retrovirus in leukemogenesis, we studied *np*9 and *gag* gene expression of HERV-K in Chronic Lymphocytic Leukemia (CLL) patients compared to healthy donors.

The results revealed that 70% of CLL patients express *np*9 gene at least 5 times higher than healthy donors, and 33% express *gag* gene twice as high as normal donors. These findings suggest a significant relationship between CLL disease and HERV-K *np*9 (and possibly *gag*) expression.

2. Materials and methods {#s0010}
========================

Peripheral blood samples were obtained from 25 patients with a typical diagnosis of B cell-CLL (mean age: 64 years). The control group consisted of 6 healthy volunteers. All patients were followed at the Hospital Maciel from Montevideo and provided an informed consent in accordance with national ethical regulations and the Declaration of Helsinki.

The peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on Ficoll-Hypaque (GE Healthcare). RNA was isolated from 1 to 5×10^6^ cells using the Trizol RNA Isolation Protocol. To minimize genomic DNA contamination each RNA sample was treated with DNA-free™ Kit (Ambion, USA). cDNA synthesis was performed as described previously [@bib7]. Negative controls in which reverse transcriptase was omitted were performed to confirm the exclusion of residual genomic DNA contamination.

For gene expression analyses of *np*9 and *gag* genes, we used the KAPA SYBR FAST qPCR Kit Master Mix (2×) Universal (Kapa Biosystems) and a Corbett Rotor-Gene 6000. HERVs-K primer sequences of *np*9 and *gag* were previously described [@bib2; @bib8]. The cellular *c-myc* expression level in CLL patients was also assessed with respect to healthy donors. The results of HERV-K and *c-myc* expression were normalized to the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcription using the following primers: forward: 5′- GGTGCTGAGTATGTCGTGGA-3′ and reverse: 5′-ATGCCAGTGAGCTTCCCGTT-3′.

PCR cycling conditions for *np*9, *c-myc* and GAPDH amplification were: 3 min at 95 °C and 40 cycles at 95 °C for 3 s, 58 °C for 20 s and 72 °C for 20 s. For HERV-K *gag* specific amplification, cycling conditions were: 95 °C for 10 min, 40 cycles at 95 °C for 15 s and 60 °C for 1 min. The threshold cycle value (Ct), computed for each of these genes as the average of 2 determinations was used to measure the amount of PCR product. The mean ΔCt was calculated by subtracting the mean Ct of duplicated *np*9 and *gag* measurements from the mean Ct of duplicated GAPDH measurements. The ΔΔCt values were calculated with the mean ΔCt of the 6 healthy donors. The expression factor difference was calculated by the formula 2^−ΔΔCt^. Thus, the calculated relative expression provides data on how much *np*9 *and gag* gene expression differs from that found in healthy donors.

3. Results and discussion {#s0015}
=========================

In this study, the *np*9 and *gag* mRNA expression was established for 25 patients with CLL ([Fig. 1](#f0005){ref-type="fig"}). We found that the transcriptional activity of HERV-K *np*9 gene in CLL patients was higher than in PBMCs from healthy donors. The results revealed that 18 out of 25 CLL patients (70% of CLL patients) express *np*9 transcripts five-fold higher than in normal PBMCs ([Fig. 1](#f0005){ref-type="fig"}A). On the other hand when we analyzed *gag* gene expression we noted that just 33% of CLL patients expressed elevated *gag* levels (two-fold) compared to healthy people ([Fig. 1](#f0005){ref-type="fig"}B). Both in *np*9 and *gag* analysis, a wide variability of expression among patients was observed, with no significant difference between mutated and unmutated subgroups (*p*=0.65 and 0.09 respectively) (see [Fig. 1](#f0005){ref-type="fig"}).

A previous study regarding HERV-K *gag* transcriptional activity [@bib2] reported five to eight-fold higher gene expression in 3 B-CLL patients analyzed. However, our study on a large number of B-CLL patients showed that only 2 out of 25 patients exhibited elevated *gag* expression (5-fold greater than healthy donors) (see [Fig. 1](#f0005){ref-type="fig"}B).

The overexpression of HERV-K Np9 protein has been observed in a variety of leukemia cell lines and primary cultures of leukemia cells [@bib3]. It is known that the interaction of Np9 protein abrogates the function of the promyelocytic leukemia zinc finger (PLZF) as a transcriptional repressor of the *c-myc* proto-oncogene promoter, resulting in the overproduction of this transcription factor and the induction of cell proliferation [@bib9]. Studies of Palacios et al. [@bib10] in CLL report that the proliferative behavior of a small CLL B-cells subpopulation could be related to expression of *c-myc* oncogene. Unfortunately our studies on *c-myc* gene expression levels in CLL patients with high and low *np*9 mRNA expressions showed no significant differences (*p*=0.19) in the expression of *c-myc* between these groups, nor with normal PBMCs ([Fig. 2](#f0010){ref-type="fig"}). The differences in these results could be explained by the distinct CLL subpopulations analyzed in each work. Other plausible explanation is that *np*9 mRNA might not be translated or alternatively, that over expression of *c-myc* through a putative Np9 PLZF pathway may be transient [@bib9].

To our knowledge, this is the first study of HERV-K *np*9 mRNA expression in B cell-CLL showing that this molecule is overexpressed in the peripheral blood of CLL patients compared with healthy donors. More studies are needed to evaluate the potential impact of *np*9 expression on CLL and its role in the regulation of signaling pathways involved in carcinogenesis.

Conflict of interests {#s0020}
=====================

The authors declare that they do not have competing interests.

Authors׳ contributions {#s0025}
======================

PM conceived the study, and participated in its design and coordination. SF has made substantial contributions to the design of the study, acquisition of data and analysis. NE and JC have been involved in revising the manuscript critically for important intellectual content. PM and SF wrote the paper. GM, GD and PO made substantial and fundamental contributions to the interpretation and discussion of the results found in this work. AL contributed collecting the samples and selecting the patients. All authors read and approved the final manuscript.

This work was supported by Fondo Clemente Estable (Grant FCE_6569) from Agencia Nacional de Investigación e Innovación (ANII) and PEDECIBA, Uruguay.

![*np*9 and *gag* mRNA relative expression levels in CLL patients with mutated and unmutated profile in their immunoglobulin Vh genes. (A) Relative expression of HERV-K *np*9 gene with respect to healthy donors. The dotted line represents the maximum value of *np*9 expression from healthy donors as a negative calibrator. (B) Relative expression of HERV-K *gag* gene with respect to healthy donors. The dotted line represents the maximum value of *gag* expression from healthy donors as a negative calibrator. The vertical error bars represent the maximum value of each CLL patient׳s sample measured by duplicated.](gr1){#f0005}

![Relative *c-myc* gene expression normalized to GAPDH expression in CLL patients with high and low *np*9 expression levels. The horizontal bars represent the median and the error bars the interquartile range. There is no significant differences (*p*=0.19) in the expression of *c-myc* gene between the analyzed groups.](gr2){#f0010}
